Amivantamab + Lazertinib (MARIPOSA) — 1L EGFR-mut NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-AMIVANTAMAB DRUG-LAZERTINIB |
|---|
| ID | REG-AMI-LAZ-NSCLC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-MARIPOSA-CHO-2024 SRC-NCCN-NSCLC-2025 |
Notes
MARIPOSA (Cho NEJM 2024, NCT04487080): amivantamab + lazertinib vs osimertinib monotherapy in 1L EGFR-mutated (ex19del or L858R) advanced NSCLC (n=1074 across three arms). Median PFS 23.7 vs 16.6 mo (HR 0.70; p<0.001) by BICR. ORR 86% vs 85%; median DoR 25.8 vs 16.8 mo. Significant added toxicity vs osimertinib alone: VTE ~37% any-grade (DOAC prophylaxis mandatory first 4 mo), rash, paronychia, infusion reactions. Basis for FDA approval Aug 2024 as 1L alternative to osimertinib monotherapy. SC amivantamab (PALOMA-3) preferred where available — IRR rate <10% vs ~65% IV. Distinct from MARIPOSA-2 (2L post-osi) regimen (REG-AMIVANTAMAB-LAZERTINIB-NSCLC-2L) which uses split-day cycle 1 with chemotherapy-combo arms. STUB pending §6.1 sign-off.
Used By
Indication
IND-NSCLC-EGFR-1L-AMI-LAZ- IND-NSCLC-EGFR-1L-AMI-LAZ